GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » Selling, General, & Admin. Expense

INBX (Inhibrx Biosciences) Selling, General, & Admin. Expense : $126.71 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Inhibrx Biosciences's selling, general, & admin. expense for the three months ended in Dec. 2024 was $16.66 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2024 was $126.71 Mil.


Inhibrx Biosciences Selling, General, & Admin. Expense Historical Data

The historical data trend for Inhibrx Biosciences's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences Selling, General, & Admin. Expense Chart

Inhibrx Biosciences Annual Data
Trend Dec22 Dec23 Dec24
Selling, General, & Admin. Expense
15.04 29.38 127.91

Inhibrx Biosciences Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only 7.83 8.78 93.37 7.90 16.66

Competitive Comparison of Inhibrx Biosciences's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Inhibrx Biosciences's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhibrx Biosciences's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Inhibrx Biosciences's Selling, General, & Admin. Expense falls into.


;
;

Inhibrx Biosciences Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $126.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inhibrx Biosciences  (NAS:INBX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Inhibrx Biosciences Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Inhibrx Biosciences's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibrx Biosciences Business Description

Industry
Traded in Other Exchanges
N/A
Address
11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.